Aderbasib

Aderbasib
Skeletal formula of aderbasib
Clinical data
Routes of
administration		Oral
ATC code
  • None
Legal status
Legal status
  • Investigational
Identifiers
  • methyl (6S,7S)-7-(hydroxycarbamoyl)-6-[(4-phenyl-1-piperazinyl)carbonyl]-5-azaspiro[2.5]octane-5-carboxylate
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H28N4O5
Molar mass416.478 g·mol−1
3D model (JSmol)
  • COC(=O)N1CC2(CC2)C[C@@H]([C@H]1C(=O)N3CCN(CC3)C4=CC=CC=C4)C(=O)NO
  • InChI=1S/C21H28N4O5/c1-30-20(28)25-14-21(7-8-21)13-16(18(26)22-29)17(25)19(27)24-11-9-23(10-12-24)15-5-3-2-4-6-15/h2-6,16-17,29H,7-14H2,1H3,(H,22,26)/t16-,17-/m0/s1
  • Key:DJXMSZSZEIKLQZ-IRXDYDNUSA-N

Aderbasib (codenamed INCB7839) is a sheddase inhibitor that may suppress tumor cell proliferation.[1] Acting on multiple receptor classes and subclasses, aderbasib is observed to regulate the tumor necrosis factor of cancer cells.[2] Aderbasib was being developed by Incyte as a potential adjunctive treatment for metastatic breast cancer. Development was halted in 2011 after positive findings from Phase II trials were contradicted by further research.[3][4]

More specifically, aderbasib is an inhibitor of ADAM10 and ADAM17.[5]

References

  1. ^ "STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL" (PDF). Ama-assn.org. Retrieved 2012-10-13.
  2. ^ "Aderbasib | CAS#791828-58-5". MedKoo. Retrieved 2012-10-13.
  3. ^ Incyte (2011-09-19). "UBS 2011 Global Life Sciences Conference". Retrieved 2013-02-13.
  4. ^ "Incyte Reports Third Quarter 2011 Financial Results And Provides Update On Key Clinical Programs" (Press release). BusinessWire. 2011-10-27. Retrieved 2013-02-13.
  5. ^ Yang L, Bhattacharya A, Li Y, Sexton S, Ling X, Li F, et al. (June 2022). "Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer". Journal of Experimental & Clinical Cancer Research. 41 (1): 184. doi:10.1186/s13046-022-02389-z. PMC 9161494. PMID 35650607.
Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by adding missing information.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.